Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

Core Insights - Viatris Inc. announced topline data from a Phase 3 study of pimecrolimus 0.3% ophthalmic ointment for blepharitis, a common eye condition characterized by eyelid inflammation [1] - The trial did not meet its primary endpoint of complete resolution of debris after six weeks of treatment [2] - The company is evaluating next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study [3] Product Development - Viatris is focused on delivering novel therapies such as Tyrvaya and Ryzumvi while progressing a differentiated pipeline [3] - In June, Viatris and Opus Genetics announced topline results from the VEGA-3 trial evaluating MR-141 for presbyopia treatment [4] - MR-141 showed that more patients achieved significant visual acuity gains compared to placebo at various time points [5][6] Market Performance - Viatris shares have an average 1-year price target of $10, indicating an expected upside of 11.86% [7] - At the time of publication, Viatris shares were down 3.94% at $8.90 [7]